These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31382533)

  • 1. Vesicular-Bound HLA-G as a Predictive Marker for Disease Progression in Epithelial Ovarian Cancer.
    Schwich E; Rebmann V; Horn PA; Celik AA; Bade-Döding C; Kimmig R; Kasimir-Bauer S; Buderath P
    Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31382533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Vesicular-bound HLA-G as Noninvasive Predictive Biomarker of CLAD After Lung Transplantation.
    Brugière O; Dreyfuss D; Guilet R; Rong S; Hirschi S; Renaud-Picard B; Reynaud-Gaubert M; Coiffard B; Bunel V; Messika J; Demant X; Le Pavec J; Dauriat G; Saint Raymond C; Falque L; Mornex JF; Tissot A; Lair D; Le Borgne Krams A; Bousseau V; Magnan A; Picard C; Roux A; Glorion M; Carmagnat M; Gazeau F; Aubertin K; Carosella E; Vallée A; Landais C; Rouas-Freiss N; LeMaoult J;
    Transplantation; 2024 Sep; ():. PubMed ID: 39294868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer.
    Buderath P; Schwich E; Jensen C; Horn PA; Kimmig R; Kasimir-Bauer S; Rebmann V
    Front Oncol; 2019; 9():1015. PubMed ID: 31681568
    [No Abstract]   [Full Text] [Related]  

  • 4. The prognostic impact of soluble and vesicular HLA-G and its relationship to circulating tumor cells in neoadjuvant treated breast cancer patients.
    König L; Kasimir-Bauer S; Hoffmann O; Bittner AK; Wagner B; Manvailer LF; Schramm S; Bankfalvi A; Giebel B; Kimmig R; Horn PA; Rebmann V
    Hum Immunol; 2016 Sep; 77(9):791-9. PubMed ID: 26796737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.
    Pierre ME; Manneh R; Hernández A; Rodríguez J; Fletcher AV; Ramírez HM; Niño OM; Gómez DA; Sanabria D; Contreras F; Pieschacón JR; Calderón PH
    Rev Colomb Obstet Ginecol; 2024 Jun; 75(1):. PubMed ID: 39013199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting chemoresponsiveness in epithelial ovarian cancer patients using circulating small extracellular vesicle-derived plasma gelsolin.
    Gerber E; Asare-Werehene M; Reunov A; Burger D; Le T; Carmona E; Mes-Masson AM; Tsang BK
    J Ovarian Res; 2023 Jan; 16(1):14. PubMed ID: 36642715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The extracellular vesicular pseudogene LGMNP1 induces M2-like macrophage polarization by upregulating LGMN and serves as a novel promising predictive biomarker for ovarian endometriosis recurrence.
    Sun SG; Guo JJ; Qu XY; Tang XY; Lin YY; Hua KQ; Qiu JJ
    Hum Reprod; 2022 Mar; 37(3):447-465. PubMed ID: 34893848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Amounts of Total and Extracellular Vesicle-Derived Soluble HLA-G are Associated with HLA-G 14-bp Deletion Variant in Women with Embryo Implantation Failure.
    Nardi Fda S; Slowik R; Michelon T; Manvailer LF; Wagner B; Neumann J; Horn P; Bicalho Mda G; Rebmann V
    Am J Reprod Immunol; 2016 Jun; 75(6):661-71. PubMed ID: 26959830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-G 3' untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer.
    Schwich E; Rebmann V; Michita RT; Rohn H; Voncken JW; Horn PA; Kimmig R; Kasimir-Bauer S; Buderath P
    Sci Rep; 2019 Apr; 9(1):5407. PubMed ID: 30932005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated levels of extracellular vesicles are associated with therapy failure and disease progression in breast cancer patients undergoing neoadjuvant chemotherapy.
    König L; Kasimir-Bauer S; Bittner AK; Hoffmann O; Wagner B; Santos Manvailer LF; Kimmig R; Horn PA; Rebmann V
    Oncoimmunology; 2017; 7(1):e1376153. PubMed ID: 29296534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating CD14
    Stenzel AE; Abrams SI; Joseph JM; Goode EL; Tario JD; Wallace PK; Kaur D; Adamson AK; Buas MF; Lugade AA; Laslavic A; Taylor SE; Orr B; Edwards RP; Elishaev E; Odunsi K; Mongiovi JM; Etter JL; Winham SJ; Kaufmann SH; Modugno F; Moysich KB
    Am J Reprod Immunol; 2021 Mar; 85(3):e13343. PubMed ID: 32905653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble HLA-G and HLA-G Bearing Extracellular Vesicles Affect ILT-2 Positive and ILT-2 Negative CD8 T Cells Complementary.
    Schwich E; Hò GT; LeMaoult J; Bade-Döding C; Carosella ED; Horn PA; Rebmann V
    Front Immunol; 2020; 11():2046. PubMed ID: 32973812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and future role of circulating tumor cells in patients with epithelial ovarian cancer.
    Van Berckelaer C; Brouwers AJ; Peeters DJ; Tjalma W; Trinh XB; van Dam PA
    Eur J Surg Oncol; 2016 Dec; 42(12):1772-1779. PubMed ID: 27265041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients.
    Heinze K; Rengsberger M; Gajda M; Jansen L; Osmers L; Oliveira-Ferrer L; Schmalfeldt B; Dürst M; Häfner N; Runnebaum IB
    Clin Epigenetics; 2021 Jan; 13(1):15. PubMed ID: 33482905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse.
    Hoffmann O; Wormland S; Bittner AK; Collenburg M; Horn PA; Kimmig R; Kasimir-Bauer S; Rebmann V
    J Cancer Res Clin Oncol; 2023 Mar; 149(3):1159-1174. PubMed ID: 35366112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer.
    Pearl ML; Zhao Q; Yang J; Dong H; Tulley S; Zhang Q; Golightly M; Zucker S; Chen WT
    Gynecol Oncol; 2014 Sep; 134(3):581-90. PubMed ID: 24972191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated serum interleukin-37 level is a predictive biomarker of poor prognosis in epithelial ovarian cancer patients.
    Huo J; Hu J; Liu G; Cui Y; Ju Y
    Arch Gynecol Obstet; 2017 Feb; 295(2):459-465. PubMed ID: 27975129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.
    Qi Y; Zhang Y; Shi Y; Yao S; Dai M; Cai H
    Technol Cancer Res Treat; 2022; 21():15330338221104565. PubMed ID: 35929135
    [No Abstract]   [Full Text] [Related]  

  • 19. Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer.
    Yu S; Yang R; Xu T; Li X; Wu S; Zhang J
    Gynecol Oncol; 2022 Nov; 167(2):342-353. PubMed ID: 36114029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Extracellular Vesicles in Epithelial Ovarian Cancer: A Systematic Review.
    Lucidi A; Buca D; Ronsini C; Tinari S; Bologna G; Buca D; Leombroni M; Liberati M; D'Antonio F; Scambia G; Lanuti P; Petrillo M
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33228245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.